Author: therawinformant

  • The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings

    The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More EarningsBiotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY) GlaxoSmithKline plc (NYSE: GSK) won a joint $2.1 billion U.S. federal funding award.Here're the key catalysts for the unfolding week:Conferences72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8PDUFA DatesFDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through.Trevena Inc (NASDAQ: TRVN) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.FDA is also due to rule on Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) exertional heat stroke drug ryanodex Saturday. The original PDUFA date was pushed back a month as the FDA finds it hard to keep up with scheduling commitments due to COVID-19.Clinical ReadoutsBioSig Technologies Inc's (NASDAQ: BSGM) CEO Kenneth Londoner, will present at the Proactive Investors One2One Virtual Event Tuesday an update on Phase 2 clinical study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19.Novavax, Inc. (NASDAQ: NVAX) is scheduled to announce in the first week of August preliminary Phase 1 data for NVX-CoV2373, its investigational vaccine against SARS-CoV-2.EarningsView more earnings on NVAXMonday Ligand Pharmaceuticals Inc. (NASDAQ: LGND) (before the market open) Minerva Neurosciences Inc (NASDAQ: NERV) (before the market open) Pacific Biosciences of California Inc (NASDAQ: PACB) (after the close) SI-Bone Inc (NASDAQ: SIBN) (after the close) Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the close) DURECT Corporation (NASDAQ: DRRX) (after the close) Penumbra Inc (NYSE: PEN) (after the close) Revance Therapeutics Inc (NASDAQ: RVNC) (after the close)Tuesday Haemonetics Corporation (NYSE: HAE) (before the market open) Incyte Corporation (NASDAQ: INCY) (before the market open) Karyopharm Therapeutics Inc (NASDAQ: KPTI) (before the market open) Intersect ENT Inc (NASDAQ: XENT) (before the market open) Oxford Immunotec Global PLC (NASDAQ: OXFD) (before the market open) Epizyme Inc (NASDAQ: EPZM) (before the market open) Neuronetics Inc (NASDAQ: STIM) (before the market open) Mallinckrodt PLC (NYSE: MNK) (before the market open) Evofem Biosciences Inc (NASDAQ: EVFM) (before the market open) Zimmer Biomet Holdings Inc (NYSE: ZBH) (before the market open) Strongbridge Biopharma plc (NASDAQ: SBBP) (before the market open) BIO-TECHNE Corp (NASDAQ: TECH) (before the market open) Avanos Medical Inc (NYSE: AVNS) (before the market open) Amarin Corporation plc (NASDAQ: AMRN) (before the market open) Aquestive Therapeutics Inc (NASDAQ: AQST) (after the close) Akcea Therapeutics Inc (NASDAQ: AKCA) (after the close) Acorda Therapeutics Inc (NASDAQ: ACOR) (after the close) (after the close) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the close) Corcept Therapeutics Incorporated (NASDAQ: CORT) (after the close) Xencor Inc (NASDAQ: XNCR) (after the close) Vapotherm Inc (NYSE: VAPO) (after the close) Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) (after the close) NuVasive, Inc. (NASDAQ: NUVA) (after the close) Qiagen NV (NYSE: QGEN) (after the close) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the close) Fulgent Genetics Inc (NASDAQ: FLGT) (after the close) Enanta Pharmaceuticals Inc (NASDAQ: ENTA) (after the close) Otonomy Inc (NASDAQ: OTIC) (after the close) Inspire Medical Systems Inc (NYSE: INSP) (after the close) Myokardia Inc (NASDAQ: MYOK) (after the close) Curis, Inc. (NASDAQ: CRIS) (after the close) CareDx Inc (NASDAQ: CDNA) (after the close) Cardiovascular Systems Inc (NASDAQ: CSII) (after the close) Cytosorbents Corp (NASDAQ: CTSO) (after the close) GenMark Diagnostics, Inc (NASDAQ: GNMK) (after the close) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) (after the close) Cerus Corporation (NASDAQ: CERS) (after the close) Inspire Medical Systems Inc (NYSE: INSP) (after the close)See also: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates Wednesday Constellation Pharmaceuticals Inc (NASDAQ: CNST) (before the market open) Vericel Corp (NASDAQ: VCEL) (before the market open) Oyster Point Pharma Inc (NASDAQ: OYST) (before the market open) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) PPD Inc (NASDAQ: PPD) (before the market open) Horizon Therapeutics PLC (NASDAQ: HZNP) (before the market open) Moderna Inc (NASDAQ: MRNA) (before the market open) Ionis Pharmaceuticals Inc (NASDAQ: IONS) (before the market open) Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the market open) Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open) IVERIC bio Inc (NASDAQ: ISEE) (before the market open) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (before the market open) BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (before the market open) Allogene Therapeutics Inc (NASDAQ: ALLO (before the market open) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA (after the close) ADMA Biologics Inc (NASDAQ: ADMA) (after the close) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (after the close) AxoGen, Inc Common Stock (NASDAQ: AXGN) (after the close) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (after the close) Global Blood Therapeutics Inc (NASDAQ: GBT) (after the close) Transenterix Inc (NYSE: TRXC) (after the close) Kindred Biosciences Inc (NASDAQ: KIN) (after the close) ResMed Inc. (NYSE: RMD) (after the close) Silk Road Medical Inc (NASDAQ: SILK) (after the close) Tricida Inc (NASDAQ: TCDA) (after the close) SurModics, Inc. (NASDAQ: SRDX) (after the close) Immunomedics, Inc. (NASDAQ: IMMU) (after the close) PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close) Sangamo Therapeutics Inc (NASDAQ: SGMO) (after the close) TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the close) Lyra Therapeutics Inc (NASDAQ: LYRA) (after the close) Miragen Therapeutics Inc (NASDAQ: MGEN) (after the close) Zogenix, Inc. (NASDAQ: ZGNX) (after the close) Sarepta Therapeutics Inc (NASDAQ: SRPT) (after the close) Natera Inc (NASDAQ: NTRA) (after the close) OraSure Technologies, Inc. (NASDAQ: OSUR) (after the close) Orthopediatrics Corp (NASDAQ: KIDS) (after the close) G1 Therapeutics Inc (NASDAQ: GTHX) (after the close) Globus Medical Inc (NYSE: GMED) (after the close) TransMedics Group Inc (NASDAQ: TMDX) (after the close) Nevro Corp (NYSE: NVRO) (after the close) Collegium Pharmaceutical Inc (NASDAQ: COLL) (after the close) Endo International PLC (NASDAQ: ENDP) (after the close)Thursday Polarityte Inc (NASDAQ: PTE) (before the market open) Mylan NV (NASDAQ: MYL) (before the market open) Menlo Therapeutics Inc (NASDAQ: MNLO) (before the market open) Mediwound Ltd (NASDAQ: MDWD) (before the market open) Synlogic Inc (NASDAQ: SYBX) (before the market open) Zoetis Inc (NYSE: ZTS) (before the market open) TherapeuticsMD Inc (NASDAQ: TXMD) (before the market open) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open) Syneos Health Inc (NASDAQ: SYNH) (before the market open) Orthofix Medical Inc (NASDAQ: OFIX) (before the market open) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) (before the market open) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) (before the market open) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (before the market open) Athenex Inc (NASDAQ: ATNX) (before the market open) Amneal Pharmaceuticals Inc (NYSE: AMRX) (before the market open) Bristol-Myers Squibb Co (NYSE: BMY) (before the market open) Agenus Inc (NASDAQ: AGEN) (before the market open) ABIOMED, Inc. (NASDAQ: ABMD) (before the market open) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (before the market open) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) PDL BioPharma Inc (NASDAQ: PDLI) (after the close) Syndax Pharmaceuticals Inc (NASDAQ: SNDX) (after the close)Regenxbio Inc Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close) Accelerate Diagnostics Inc (NASDAQ: AXDX) (after the close) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (after the close) Achieve Life Sciences Inc (NASDAQ: ACHV) (after the close) Acceleron Pharma Inc (NASDAQ: XLRN) (after the close) Coherus Biosciences Inc (NASDAQ: CHRS) (after the close) Puma Biotechnology Inc (NASDAQ: PBYI) (after the close) Axonics Modulation Technologies Inc (NASDAQ: AXNX) (after the close) Theravance Biopharma Inc (NASDAQ: TBPH) (after the close) Iovance Biotherapeutics Inc (NASDAQ: IOVA) (after the close) Glaukos Corp (NYSE: GKOS) (after the close) CytomX Therapeutics Inc (NASDAQ: CTMX) (after the close) Cytokinetics, Inc. (NASDAQ: CYTK) (after the close) Insulet Corporation (NASDAQ: PODD) (after the close) Chembio Diagnostics Inc (NASDAQ: CEMI) (after the close) Exelixis, Inc. (NASDAQ: EXEL) (after the close) Editas Medicine Inc (NASDAQ: EDIT) (after the close) FibroGen, Inc. (NASDAQ: FGEN) (after the close) Guardant Health Inc (NASDAQ: GH) (after the close) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) (after the close) PRA Health Sciences Inc (NASDAQ: PRAH) (after the close) Illumina, Inc. (NASDAQ: ILMN) (after the close) Insmed Incorporated (NASDAQ: INSM) (after the close) Pfenex Inc (NYSE: PFNX) (after the close) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) (after the close) Spero Therapeutics Inc (NASDAQ: SPRO) (after the close) NovaBay Pharmaceuticals, Inc. (NYSE: NBY) (after the close) Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close) Nektar Therapeutics (NASDAQ: NKTR) (after the close)Friday Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) Meridian Bioscience, Inc. (NASDAQ: VIVO) (before the market open) Ocular Therapeutix Inc (NASDAQ: OCUL) (before the market open)IPO Quiet Period Expiry• Poseida Therapeutics, Inc. (NASDAQ: PSTX) • Nkarta Inc (NASDAQ: NKTX)Related Link: Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity See more from Benzinga * The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter * The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings * Novavax Strikes Coronavirus Vaccine Manufacturing Deal, Pushes Back Release Of Phase 1 Data(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2D2BCeT

  • Thoughts On Nvidia Corp (NVDA)

    from Yahoo Finance https://ift.tt/30nTOse

  • Top 5 Robotics and Artificial Intelligence Stocks To Buy According to Hedge Funds

    Top 5 Robotics and Artificial Intelligence Stocks To Buy According to Hedge FundsWhat are the best robotics and artificial intelligence stocks to buy today? In this time of uncertainty characterized by volatile market movements, economic contraction, and spiraling unemployment, finding stocks to put your money into seems like an arduous task. Some investors might think that the stock market is acting irrationally and puzzled by the quick […]

    from Yahoo Finance https://ift.tt/2XlkOGD

  • MARKETS: Nasdaq, S&P 500 close July at record monthly highs — YF Premium is bullish on Starbux (SBUX)

    MARKETS: Nasdaq, S&P 500 close July at record monthly highs — YF Premium is bullish on Starbux (SBUX)Yahoo Finance’s Jared Blikre joins Myles Udland to break down the day’s price action in stocks as well as a long in Starbux (SBUX), a Yahoo Finance Premium Investment Idea.

    from Yahoo Finance https://ift.tt/3fg5PUv

  • Amazon earns FCC approval to launch $10B satellite project

    Amazon earns FCC approval to launch $10B satellite projectThe FCC approved Amazon’s Project Kuiper, allowing the tech company to operate a constellation of 3,236 satellites. Yahoo Finance’s Dan Howley shares the details.

    from Yahoo Finance https://ift.tt/2D9MhV1

  • New Forecasts: Here’s What Analysts Think The Future Holds For Quidel Corporation (NASDAQ:QDEL)

    New Forecasts: Here's What Analysts Think The Future Holds For Quidel Corporation (NASDAQ:QDEL)Celebrations may be in order for Quidel Corporation (NASDAQ:QDEL) shareholders, with the analysts delivering a…

    from Yahoo Finance https://ift.tt/33kNQtU

  • This week in Trumponomics

    This week in TrumponomicsThe coronavirus recession began with the sharpest economic contraction on record—a 32.9% drop in second quarter GDP. Yahoo Finance’s Rick Newman joined The Final Round to discuss why he thinks the V-shaped recovery is gone and gives this week’s Trumpometer reading.

    from Yahoo Finance https://ift.tt/3fkeDJl

  • Chevron CFO: We’re in a position to support our dividend

    Chevron CFO: We’re in a position to support our dividendChevron CFO Pierre Breber joins Yahoo Finance’s Julia La Roche to discuss the company’s latest quarterly earnings results after Chevron’s CEO noted COVID-19 has “significantly reduced demand.”

    from Yahoo Finance https://ift.tt/3fqgxrz

  • July jobs report, Disney earnings and more: What to know in the week ahead

    July jobs report, Disney earnings and more: What to know in the week aheadEarnings season continues this week with another packed calendar for quarterly results. Meanwhile, the July jobs report is set for release Friday.

    from Yahoo Finance https://ift.tt/2DbADsH

  • Analysts Say These 2 Stocks Are Their Top Picks for the Rest of 2020

    Analysts Say These 2 Stocks Are Their Top Picks for the Rest of 2020There’s no denying it, 2020 has been a strange year. A viral outbreak rocked the world to its core, laying waste to the global economy. At the same time, amid violent bursts of volatility, stocks revved their engines and sped forward, seemingly brushing off all of the chaos unfolding in the background. Rebounding vigorously off of March lows, the S&P 500 has crossed over into positive territory for the year so far. Making it that much more difficult to predict the market’s trajectory, COVID-19 isn’t going away any time soon, with the virus making a reappearance in several parts of the world. As so many unknowns remain, finding compelling plays can feel like Mission Impossible. That being said, Wall Street analysts tell investors there are still some exciting opportunities to be found. Using TipRanks’ database, we’ve locked in on two such stocks, beloved by the pros that cover them, so much so that they have been deemed top picks for the remainder of 2020. The rest of the Street also backs both tickers, with each sporting a “Strong Buy” consensus rating. Truist Financial (TFC) With roughly $504 billion in assets, Truist Financial is one of the largest bank holding companies in the U.S., offering a full range of consumer and commercial banking, securities brokerage, asset management, mortgage and insurance products and services. As lower LLP is expected, several members of the Street have high hopes. Representing BMO Capital, four-star analyst Lana Chan tells clients “TFC remains our top pick among the Regionals given its PPNR strength and ACL coverage,” with it having “appropriately front-loaded the reserve build in 1H20 based on the current economic outlook.” To support her bullish stance, Chan cites management’s guidance for Q3. The company guided for a revenue decline of 3-5% from last quarter, with core noninterest expenses also set to be down. NCOs are expected to land within the range of 45-65 basis points, compared to 39 basis points in Q2. Reported NIM should also be relatively stable, following a larger-than-expected 45-basis point decline in Q2. This is because TFC has room to lower deposit costs and has instituted floors on new loans. “Noninterest income trends will be mixed with a partial rebound in deposit service charges and card income, but seasonally lower insurance and mortgage banking revenue and a tough comparison versus Q2's strength in capital markets,” Chan added. Adding to the good news, the company has placed a significant focus on achieving its net cost savings target of $1.6 billion by Q4 2022, with 40% slated to be achieved by Q4 2020 (vs. 30% previously) and 65% achieved by Q4 2021. To ramp up the cost reductions, TFC is trimming personnel, corporate real estate and third-party vendor expenses. Additionally, the company isn’t expected to incur more COVID-19-related costs. Representing another positive, Chan stated, “TFC has a large cushion to absorb credit losses, with its ACL and unamortized loan mark totaling a peer-leading 60% of estimated DFAST losses. It was proactive with risk ratings on its commercial loan book in Q2, as reflected in its reserve build.” It should be noted that TFC has granted forbearance on 11.2% of loans, and disclosed COVID-19 “at-risk” industries account for 9.6% of total loans. This means there’s a “risk of a large part of its Southeast footprint reclosing in a second COVID-19 wave,” in Chan’s opinion. However, everything else that TFC has going for it keeps Chan with the bulls. To this end, she maintained an Outperform rating. She also gave the price target a boost, raising it from $42 to $47, suggesting 25% upside potential. (To watch Chan’s track record, click here) Judging by the consensus breakdown, other analysts also like what they’re seeing. 7 Buys and 2 Holds add up to a Strong Buy consensus rating. The $44 average price target puts the upside potential at 17%. (See Truist Financial stock analysis on TipRanks) Dollar General Corporation (DG) Boasting more than 16,000 stores, Dollar General counts itself as one of the top discount retailers in the U.S. With some analysts arguing the market is undervaluing the company, now could be the ideal time to get in on the action. Five-star analyst Rupesh Parikh, of Oppenheimer, is singing a different tune after reevaluating DG’s long-term growth prospects. Even though it has already posted a 22% year-to-date gain, the analyst sees even more upside on the horizon. “Based on our work, we believe the market is still underappreciating the company's long-term earnings power, following the recent grocery boom, traction from management initiatives, and lasting market share gains coming out of the coronavirus pandemic,” Parikh commented. According to Parikh, in the near-term, elevated comp growth is likely. To support this claim, he cites the expected growth “in at home food consumption, management initiatives, government stimulus, and benefits from consumer trade-down in a potentially weaker economic environment to drive comps above the company's historical LSD to MSD comp delivery.” It also doesn’t hurt that these benefits and market share gains could persist in the year ahead. As for its long-term earnings power, Parikh is more optimistic than the rest of the Street. While the consensus estimate has FY20-21 EPS coming in at $8.84 and $8.87, respectively, the Oppenheimer analyst thinks the figures will land at $9.15 and $8.90. It should be noted that share buybacks and any adverse impacts related to Biden's tax and wage proposals aren’t factored into these projections. Looking more closely at the potential “blue wave” in the upcoming U.S. election, a Biden presidency would mean that the corporate tax rate would jump from 21% to 28%. This increase would negatively impact DG’s FY21 earnings by nearly 10%, based on Parikh’s estimates. He also mentioned, “In addition, an increase to the minimum wage to $15 nationally could also represent an incremental headwind, especially if implemented over a short period.” That being said, DG’s relative P/E multiple has declined to 0.97x from a recent peak of 1.19x in March 2020, making the valuation more compelling when compared to its peers. All of the above makes DG a “top pick” for Parikh. As a result, the analyst continues to assign an Outperform rating to the stock. Bumping up the price target from $205 to $225, a potential twelve-month gain of 18% could be in the cards. (To watch Parikh’s track record, click here) The bulls have it on this one. Out of 18 total reviews published in the last three months, 15 analysts rated the stock a Buy while only 3 said Hold. So, DG gets a Strong Buy consensus rating. With a $209.71 average price target, shares could surge 10% in the next twelve months. (See Dollar General stock analysis on TipRanks)

    from Yahoo Finance https://ift.tt/3hTsrfk